[
  {
    "ts": null,
    "headline": "Health Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers",
    "summary": "Today, AbbVie (NYSE: ABBV) has announced that under the Priority Review process, Health Canada has approved ELAHERE® (mirvetuximab soravtansine for injection), an antibody-drug conjugate (ADC), for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.1",
    "url": "https://finnhub.io/api/news?id=5759369807cdeb595c092913e84ae5e0a81fe57f0cb6da23997eb17d77572f2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756835040,
      "headline": "Health Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers",
      "id": 136612925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Today, AbbVie (NYSE: ABBV) has announced that under the Priority Review process, Health Canada has approved ELAHERE® (mirvetuximab soravtansine for injection), an antibody-drug conjugate (ADC), for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.1",
      "url": "https://finnhub.io/api/news?id=5759369807cdeb595c092913e84ae5e0a81fe57f0cb6da23997eb17d77572f2d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales",
    "summary": "Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.",
    "url": "https://finnhub.io/api/news?id=f7b8a5b03937a6c38486617ec514d6c3f02ebf94ec57448fba034c5c55d8e281",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756825260,
      "headline": "Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales",
      "id": 136612878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.",
      "url": "https://finnhub.io/api/news?id=f7b8a5b03937a6c38486617ec514d6c3f02ebf94ec57448fba034c5c55d8e281"
    }
  },
  {
    "ts": null,
    "headline": "GSK Adds Around $5B in a Month: Here's How to Play the Stock",
    "summary": "GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.",
    "url": "https://finnhub.io/api/news?id=028f225eea9c5d7fa896c4f3e16e91ccb5b680bafe097de3c3114efaf0fae10c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756824480,
      "headline": "GSK Adds Around $5B in a Month: Here's How to Play the Stock",
      "id": 136612879,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.",
      "url": "https://finnhub.io/api/news?id=028f225eea9c5d7fa896c4f3e16e91ccb5b680bafe097de3c3114efaf0fae10c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Gets Health Canada Approval for Ovarian-Cancer Treatment",
    "summary": "AbbVie Gets Health Canada Approval for Ovarian-Cancer Treatment",
    "url": "https://finnhub.io/api/news?id=4f9e2f30fd1a1be88123c2e96b05e71589b89883519ab603953dfc38fc4d36de",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756818120,
      "headline": "AbbVie Gets Health Canada Approval for Ovarian-Cancer Treatment",
      "id": 136618025,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Gets Health Canada Approval for Ovarian-Cancer Treatment",
      "url": "https://finnhub.io/api/news?id=4f9e2f30fd1a1be88123c2e96b05e71589b89883519ab603953dfc38fc4d36de"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference",
    "summary": "AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025. Management will participate in a fireside chat at 9:00 a.m. Central time.",
    "url": "https://finnhub.io/api/news?id=84bd81876303663dd737a3e6831e7bf28d1c054799c95e045710414f649cb51c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756818000,
      "headline": "AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference",
      "id": 136604094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025. Management will participate in a fireside chat at 9:00 a.m. Central time.",
      "url": "https://finnhub.io/api/news?id=84bd81876303663dd737a3e6831e7bf28d1c054799c95e045710414f649cb51c"
    }
  },
  {
    "ts": null,
    "headline": "Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access",
    "summary": "We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Neurocrine Biosciences, Inc. is one of them. Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on neurological, neuroendocrine, and neuropsychiatric disorders, continues to demonstrate robust growth through its FDA-approved treatments and advancing pipeline. The company’s portfolio includes […]",
    "url": "https://finnhub.io/api/news?id=1755212b1d9fe79fed6d8f985e3c8d1e1d39e07793e0cddd0a144e508563551f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756803834,
      "headline": "Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access",
      "id": 136604095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Neurocrine Biosciences, Inc. is one of them. Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on neurological, neuroendocrine, and neuropsychiatric disorders, continues to demonstrate robust growth through its FDA-approved treatments and advancing pipeline. The company’s portfolio includes […]",
      "url": "https://finnhub.io/api/news?id=1755212b1d9fe79fed6d8f985e3c8d1e1d39e07793e0cddd0a144e508563551f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Acquires Psychedelic Drug Developer Gilgamesh for $1.2B, Enters Mental Health Market",
    "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. AbbVie Inc. is one of them. AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical leader, continues to expand its presence in immunology, oncology, and neuroscience. The company has successfully transitioned from legacy drugs like Humira to newer blockbusters, including Skyrizi […]",
    "url": "https://finnhub.io/api/news?id=19243e9ca06ae17d3c515224900e87b77fa6ba731a8216c613a749ad49d95841",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756801667,
      "headline": "AbbVie Inc. (ABBV) Acquires Psychedelic Drug Developer Gilgamesh for $1.2B, Enters Mental Health Market",
      "id": 136604096,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. AbbVie Inc. is one of them. AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical leader, continues to expand its presence in immunology, oncology, and neuroscience. The company has successfully transitioned from legacy drugs like Humira to newer blockbusters, including Skyrizi […]",
      "url": "https://finnhub.io/api/news?id=19243e9ca06ae17d3c515224900e87b77fa6ba731a8216c613a749ad49d95841"
    }
  }
]